<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33040444</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1742-7843</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>128</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Basic &amp; clinical pharmacology &amp; toxicology</Title>
          <ISOAbbreviation>Basic Clin Pharmacol Toxicol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Letrozole targets the human ether-a-go-go-related gene potassium current in glioblastoma.</ArticleTitle>
        <Pagination>
          <StartPage>357</StartPage>
          <EndPage>365</EndPage>
          <MedlinePgn>357-365</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/bcpt.13515</ELocationID>
        <Abstract>
          <AbstractText>Aberrant expression of human ether-a-go-go-related gene (hERG) potassium channels has been implicated in the pathophysiology of glioblastoma (GBM). Letrozole has demonstrated efficacy in pre-clinical GBM models. The objective of this research was to assess the potential for hERG inhibition by letrozole to mediate efficacy in GBM. hERG currents were assessed using patch-clamp electrophysiology in an overexpression system during treatment with letrozole, exemestane or vehicle (dimethyl sulphoxide). Relative to vehicle, peak hERG tail current density was reduced when treated with 300 nmol/L and 1 µmol/L letrozole but not when treated with exemestane (up to 1 µmol/L). Cell proliferation was assessed in cultured glioblastoma cell lines (U87 and U373) treated with letrozole, exemestane, doxazosin (hERG blocker) or vehicle. Letrozole, but not exemestane, reduced cell proliferation relative to vehicle in U87 and U373 cells. The associations between expression of hERG (KCNH2), aromatase (CYP19A1) and the oestrogen receptors (ESR1 and ESR2) and time to all-cause mortality were assessed in GBM patients within The Cancer Genome Atlas (TCGA) database. hERG expression was associated with reduced overall survival in the TCGA GBM cohort. Future work is warranted to investigate hERG expression as a potential biomarker to predict the therapeutic potential of hERG inhibitors in GBM.</AbstractText>
          <CopyrightInformation>© 2020 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shugg</LastName>
            <ForeName>Tyler</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-5784-3565</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafayette, IN, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dave</LastName>
            <ForeName>Nimita</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amarh</LastName>
            <ForeName>Enoch</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafayette, IN, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Assiri</LastName>
            <ForeName>Abdullah A</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafayette, IN, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pollok</LastName>
            <ForeName>Karen E</ForeName>
            <Initials>KE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Overholser</LastName>
            <ForeName>Brian R</ForeName>
            <Initials>BR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafayette, IN, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K08 HL095655</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R03 HL141619</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>HL095655</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Basic Clin Pharmacol Toxicol</MedlineTA>
        <NlmUniqueID>101208422</NlmUniqueID>
        <ISSNLinking>1742-7835</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000730">Androstadienes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051638">Ether-A-Go-Go Potassium Channels</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LKK855W8I</RegistryNumber>
          <NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>NY22HMQ4BX</RegistryNumber>
          <NameOfSubstance UI="C056516">exemestane</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000730" MajorTopicYN="N">Androstadienes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051638" MajorTopicYN="N">Ether-A-Go-Go Potassium Channels</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005909" MajorTopicYN="N">Glioblastoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">carcinogenesis</Keyword>
        <Keyword MajorTopicYN="N">cardiac arrhythmias</Keyword>
        <Keyword MajorTopicYN="N">glioblastoma</Keyword>
        <Keyword MajorTopicYN="N">hERG</Keyword>
        <Keyword MajorTopicYN="N">human ether-a-go-go-related gene</Keyword>
        <Keyword MajorTopicYN="N">ion channels as drug targets</Keyword>
        <Keyword MajorTopicYN="N">letrozole</Keyword>
      </KeywordList>
      <CoiStatement>CONFLICT OF INTEREST STATEMENT. The authors have no conflicts to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>11</Day>
          <Hour>20</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33040444</ArticleId>
        <ArticleId IdType="mid">NIHMS1637881</ArticleId>
        <ArticleId IdType="pmc">PMC7889647</ArticleId>
        <ArticleId IdType="doi">10.1111/bcpt.13515</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2018;54:7–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29801989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Carlo DT, Cagnazzo F, Benedetto N, Morganti R, Perrini P. Multiple high-grade gliomas: epidemiology, management, and outcome. A systematic review and meta-analysis. Neurosurgical review. 2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29138949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paolillo M, Boselli C, Schinelli S. Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. Brain sciences. 2018;8(1).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5789346</ArticleId>
            <ArticleId IdType="pubmed">29337870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma targeted therapy: updated approaches from recent biological insights. Annals of oncology : official journal of the European Society for Medical Oncology. 2017;28(7):1457–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5834086</ArticleId>
            <ArticleId IdType="pubmed">28863449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding XW, Luo HS, Luo B, Xu DQ, Gao S. Overexpression of hERG1 in resected esophageal squamous cell carcinomas: a marker for poor prognosis. Journal of surgical oncology. 2008;97(1):57–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17786970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masi A, Becchetti A, Restano-Cassulini R, Polvani S, Hofmann G, Buccoliero AM, et al.
hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer. 2005;93(7):781–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2361632</ArticleId>
            <ArticleId IdType="pubmed">16175187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pointer KB, Clark PA, Eliceiri KW, Salamat MS, Robertson GA, Kuo JS. Administration of Non-Torsadogenic human Ether-a-go-go-Related Gene Inhibitors Is Associated with Better Survival for High hERG-Expressing Glioblastoma Patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017;23(1):73–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5627655</ArticleId>
            <ArticleId IdType="pubmed">27635088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao XD, Wu KC, Guo XZ, Xie MJ, Zhang J, Fan DM. Expression and significance of HERG protein in gastric cancer. Cancer biology &amp; therapy. 2008;7(1):45–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17938585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995;81(2):299–307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7736582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Comes N, Serrano-Albarras A, Capera J, Serrano-Novillo C, Condom E, Ramon YCS, et al.
Involvement of potassium channels in the progression of cancer to a more malignant phenotype. Biochimica et biophysica acta. 2015;1848(10 Pt B):2477–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25517985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lastraioli E, Guasti L, Crociani O, Polvani S, Hofmann G, Witchel H, et al.
herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer research. 2004;64(2):606–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14744775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jehle J, Schweizer PA, Katus HA, Thomas D. Novel roles for hERG K(+) channels in cell proliferation and apoptosis. Cell death &amp; disease. 2011;2:e193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3181422</ArticleId>
            <ArticleId IdType="pubmed">21850047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tivnan A, Heilinger T, Ramsey JM, O’Connor G, Pokorny JL, Sarkaria JN, et al.
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. Oncotarget. 2017;8(10):16605–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5369988</ArticleId>
            <ArticleId IdType="pubmed">28178667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dave N, Chow LM, Gudelsky GA, LaSance K, Qi X, Desai PB. Preclinical pharmacological evaluation of letrozole as a novel treatment for gliomas. Molecular cancer therapeutics. 2015;14(4):857–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4631403</ArticleId>
            <ArticleId IdType="pubmed">25695958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, et al.
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anti-cancer drugs. 2018;29(3):271–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5821476</ArticleId>
            <ArticleId IdType="pubmed">29360661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartz PJ, Woosley RL. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. Journal of the American College of Cardiology. 2016;67(13):1639–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27150690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tveden-Nyborg P, Bergmann TK, Lykkesfeldt J. Basic &amp; Clinical Pharmacology &amp; Toxicology Policy for Experimental and Clinical studies. Basic Clin Pharmacol Toxicol. 2018;123(3):233–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29931751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldman M, Craft B, Hastie M, Repecka K, Kamath A, McDade F, et al.
The UCSC Xena platform for public and private cancer genomics data visualization and interpretation. bioRxiv. 2019;326470.</Citation>
        </Reference>
        <Reference>
          <Citation>Anaya J
OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Computer Science. 2016;2(e67).</Citation>
        </Reference>
        <Reference>
          <Citation>Staudacher I, Jehle J, Staudacher K, Pledl HW, Lemke D, Schweizer PA, et al.
HERG K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells. PloS one. 2014;9(2):e88164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3916397</ArticleId>
            <ArticleId IdType="pubmed">24516604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desta Z, Kreutz Y, Nguyen AT, Li L, Skaar T, Kamdem LK, et al.
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clinical pharmacology and therapeutics. 2011;90(5):693–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3667657</ArticleId>
            <ArticleId IdType="pubmed">21975350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dave N, Gudelsky GA, Desai PB. The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis. Cancer Chemother Pharmacol. 2013;72(2):349–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23748921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002;20(3):751–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11821457</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
